MPJE: Multistate Pharmacy Jurisprudence Examination Quiz: Labeling Requirements
20 questions · exam conditions
0:00
Labeling RequirementsQuestion 1 of 20

A pharmacy changes computer systems and the new system prints labels without the prescriber's name. Prescriptions are being dispensed with this incomplete label. Which of the following best analyzes the compliance concern?

No compliance concern exists because patients do not need to know their prescriber's name.
The prescriber's name is required on labels by law; dispensing without it is non-compliant and must be corrected immediately.
The compliance concern is minor and may be resolved by placing a sticker with the prescriber's name on the bag.
The compliance concern applies only to controlled substance prescriptions.
← Back to quizzes

MPJE: Multistate Pharmacy Jurisprudence Examination Quiz

MPJE: Multistate Pharmacy Jurisprudence Examination Quiz: Labeling Requirements

Practice Labeling Requirements in MPJE: Multistate Pharmacy Jurisprudence Examination with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Labeling Requirements, giving you a quick way to practice the rules, question types, and explanations that matter most for MPJE: Multistate Pharmacy Jurisprudence Examination.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A pharmacy changes computer systems and the new system prints labels without the prescriber's name. Prescriptions are being dispensed with this incomplete label. Which of the following best analyzes the compliance concern?

  1. No compliance concern exists because patients do not need to know their prescriber's name.
  2. The prescriber's name is required on labels by law; dispensing without it is non-compliant and must be corrected immediately. (correct answer)
  3. The compliance concern is minor and may be resolved by placing a sticker with the prescriber's name on the bag.
  4. The compliance concern applies only to controlled substance prescriptions.
Explanation: Prescriber name is a required element under 21 CFR 201.100 and most state pharmacy laws. Labels without this element are non-compliant and must be corrected before dispensing continues. B correctly identifies this compliance concern. A is incorrect because prescriber identification is a legally required label element. C is incorrect because a bag sticker is not a substitute for the required label element. D is incorrect because prescriber name is required on all prescription dispensing labels, not only controlled substances.

Question 2

A pharmacy's computer system automatically truncates long drug names on the label. A drug name is shortened in a way that could be confused with another medication. Which of the following best applies?

  1. Truncation is acceptable because long drug names are difficult to read.
  2. Truncation is acceptable as long as the NDC number is correct on the label.
  3. Truncation causing confusion is a labeling error; drug names must be clear and unambiguous. (correct answer)
  4. Truncation is acceptable as long as the pharmacist initials the label confirming accuracy.
Explanation: Drug name clarity is essential for patient safety. Truncations that create potential confusion with another medication are labeling deficiencies that must be corrected. C correctly identifies this patient safety and compliance concern. A is incorrect because length preferences do not justify confusing truncations. B is incorrect because NDC accuracy is separate from the drug name clarity required for the patient-facing label. D is incorrect because pharmacist initials do not cure a patient-facing labeling deficiency.

Question 3

Under 21 CFR 290.5, which schedules of controlled substances require the transfer warning label 'Caution: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed'?

  1. Schedule I only.
  2. Schedules II, III, and IV. (correct answer)
  3. Schedule II only.
  4. Schedules III and IV only.
Explanation: 21 CFR 290.5 requires the transfer warning label -- 'Caution: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed' -- on dispensing labels for prescription drug products containing Schedule II, III, and IV controlled substances. B correctly identifies this scope. A is incorrect because Schedule I substances are not lawfully dispensed by retail pharmacies and are not the subject of this retail labeling requirement. C is incorrect because the requirement extends beyond Schedule II to Schedules III and IV as well. D is incorrect because it omits Schedule II, which is included in the requirement.

Question 4

A patient's prescription reads 'take one tablet twice daily' and the pharmacist prints this exactly on the label. The patient is a child and the prescriber intended a weight-based dose that was communicated verbally but not written. Which of the following best applies to this labeling situation?

  1. The pharmacist must verify and document the correct pediatric dose with the prescriber before dispensing. (correct answer)
  2. The pharmacist may add the weight-based dose to the label based on the verbal instruction.
  3. The pharmacist may dispense based on the written prescription only and need not investigate the verbal instruction.
  4. The pharmacist may add the child's weight to the label as a note and dispense the adult dose.
Explanation: The label must reflect the authorized dose, and the pharmacist has a duty to clarify a potential pediatric dosing discrepancy. For a non-controlled prescription, the pharmacist may contact the prescriber, receive a verbal clarification or change, document it in the prescription record, and dispense with a corrected label. A verbal prescriber-authorized change that is properly documented satisfies the prescription and labeling requirement. A correctly identifies this process. B is incorrect because the pharmacist may not add a weight-based dose to the label solely on the basis of an undocumented verbal statement from a non-prescriber source; the prescriber must authorize the change. C is incorrect because a potential dosing discrepancy for a pediatric patient requires clarification, not silent dispensing based on the original written directions. D is incorrect because adding a weight note does not resolve the dose discrepancy; a clarified authorized dose from the prescriber is required.

Question 5

A patient picks up a prescription and notices that the label lists the wrong patient name -- it has a similar name but is actually another patient's prescription. Under labeling requirements, which of the following is the pharmacist's obligation?

  1. The pharmacist must retrieve the prescription, correct the label, and ensure the correct patient receives the medication. (correct answer)
  2. The pharmacist may add a sticker with the correct name and dispense the prescription.
  3. The pharmacist may dispense the prescription because the patient will know it is theirs from the drug name.
  4. The pharmacist need only apologize and note the error in the system.
Explanation: A mislabeled prescription with the wrong patient name is a dispensing and labeling error requiring immediate retrieval, correction, documentation, and assessment of whether the incorrectly named patient may have received the wrong prescription. A correctly identifies this comprehensive response. B is incorrect because a sticker is not adequate correction of a mislabeled prescription; the label must be reprinted correctly. C is incorrect because patient name is a required label element and the patient cannot be expected to guess from drug name. D is incorrect because apology and notation alone without correction and investigation do not satisfy labeling and error management obligations.

Question 6

Under most state laws, a pharmacy dispenses a brand-name product when a generic is available and substitution is permitted. The prescriber did not indicate 'brand medically necessary.' Which of the following best describes the labeling obligation?

  1. The label should reflect the brand name because the brand-name product is being dispensed.
  2. The label may use either the brand or generic name at the pharmacist's discretion.
  3. The label must indicate the brand-name product was dispensed if a generic was available. (correct answer)
  4. The label must always use the generic name regardless of which product was dispensed.
Explanation: The label must accurately reflect the actual dispensed product. Some states require notation when a brand is dispensed and generic substitution was available. C correctly identifies this requirement. A is partially correct but C is more precise about the state notation requirement. B is incorrect because label accuracy is required, not pharmacist discretion. D is incorrect because the generic name is not universally required when a brand-name product was actually dispensed.

Question 7

Under FDA regulations, oral contraceptives require a patient package insert (PPI) to be dispensed with each fill. Which of the following best describes this requirement?

  1. The PPI must be provided only when a patient is starting oral contraceptives for the first time.
  2. The PPI must be provided only if the prescriber requests it.
  3. The PPI is optional and may be provided only upon patient request.
  4. The PPI must be dispensed with every fill of oral contraceptives, including refills. (correct answer)
Explanation: FDA regulations require the oral contraceptive patient package insert to be dispensed at each fill, including refills. D correctly identifies this ongoing requirement. A is incorrect because the PPI must accompany each fill, not only the first. B is incorrect because PPI dispensing is mandatory, not conditioned on prescriber request. C is incorrect because PPI provision is mandatory rather than optional.

Question 8

Under 21 CFR 201.100, which of the following is required on the label of a prescription drug dispensed to a patient?

  1. The pharmacy's name and address, prescription serial number, and usage directions. (correct answer)
  2. Only the drug name and dosage form.
  3. Only the physician's name and the patient's insurance ID number.
  4. Only the dispensing date and the pharmacist's initials.
Explanation: 21 CFR 201.100 requires the dispensing pharmacy's name and address, prescription serial number, fill date, prescriber's name, patient's name, and directions for use with cautionary statements as directed by the prescriber. A correctly identifies these federal label requirements. B is incorrect because drug name and dosage form alone are insufficient. C is incorrect because insurance ID is not a required label element. D is incorrect because date and initials alone fall far below federal requirements.

Question 9

Under most state pharmacy laws, which of the following auxiliary statements is required to appear on the dispensing label for a Schedule II or III controlled substance?

  1. A red sticker indicating the DEA schedule number of the drug.
  2. A statement that the drug is only available by prescription.
  3. Caution: Federal law prohibits transfer to anyone other than the prescribed patient. (correct answer)
  4. The pharmacist's personal cell phone number for questions about the medication.
Explanation: Federal law (21 CFR 290.5) requires the transfer warning on labels for Schedule II through V controlled substance dispensing: 'Caution: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed.' C correctly identifies this required statement. A is incorrect because a schedule sticker is not the federally required auxiliary statement for controlled substance dispensing labels. B is incorrect because prescription-only status is communicated elsewhere; the specific transfer warning is the required auxiliary statement. D is incorrect because the pharmacist's personal contact information is not a required label element.

Question 10

A pharmacy is dispensing a medication that has an FDA-required Medication Guide. Under FDA regulations, which of the following must the pharmacy do at each dispensing?

  1. Provide the Medication Guide only when dispensing the medication for the first time.
  2. Provide the Medication Guide only if the patient asks for additional information.
  3. Provide the Medication Guide with every dispensing, including refills. (correct answer)
  4. Place the Medication Guide on file at the pharmacy; patients may request it.
Explanation: FDA regulations require Medication Guides to be provided with each dispensing of the medication, including each refill. C correctly identifies this ongoing requirement. A is incorrect because the Medication Guide must be provided at each fill, not only the first. B is incorrect because dispensing is proactive and mandatory, not contingent on patient request. D is incorrect because placing the Medication Guide on file does not satisfy the requirement; it must be provided to the patient at each fill.

Question 11

Under the FDCA, which of the following best describes the concept of adequate directions for use on a prescription drug label?

  1. Adequate directions for use means a brief statement of the drug's name and category.
  2. Adequate directions for use means instructions written in a language the pharmacist prefers.
  3. Adequate directions for use means instructions enabling safe use by a layperson. (correct answer)
  4. Adequate directions for use means only the prescriber's original instructions verbatim.
Explanation: The FDCA defines adequate directions for use as those written so a layperson can use the drug safely: dose, frequency, duration, route, and special instructions in clear, understandable language. C correctly identifies this standard. A is incorrect because drug name and category alone are not adequate directions. B is incorrect because language accessibility for the patient, not pharmacist preference, governs. D is incorrect because prescriber verbatim instructions may themselves be inadequate if not clear enough for layperson use.

Question 12

Under FDCA Section 503B, what statement must appear on the label of a preparation compounded by an outsourcing facility?

  1. The label must state the drug is FDA-approved.
  2. No special labeling statement is required beyond standard dispensing elements.
  3. The label must state that the preparation was compounded in an FDA-inspected facility.
  4. The label must state "compounded by a 503B facility, not FDA-approved." (correct answer)
Explanation: Section 503B requires outsourcing facility labels to state that the product was compounded by a 503B outsourcing facility and has not been approved by the FDA. D correctly identifies these required disclosures. A is incorrect because 503B products are specifically not FDA-approved; labeling them as approved would be false. B is incorrect because the 503B-specific disclosures are specifically required. C is incorrect because the required statement is about FDA approval status, not facility inspection status.

Question 13

Under FDA regulations, auxiliary warning labels such as 'Do not take with grapefruit juice' or 'May cause drowsiness -- use caution when driving' serve which of the following purposes?

  1. Auxiliary labels are optional marketing materials with no regulatory basis.
  2. Auxiliary labels provide critical safety information about drug interactions and potential side effects. (correct answer)
  3. Auxiliary labels are required by DEA regulations for all controlled substances.
  4. Auxiliary labels are only required when a patient has a documented allergy.
Explanation: Auxiliary warning labels provide additional safety information -- drug interactions, precautions, side effect warnings -- supplementing the primary label to support safe medication use. B correctly identifies this purpose. A is incorrect because auxiliary labels serve a defined patient safety function and may be required by state law for certain drug categories. C is incorrect because DEA regulations do not specifically mandate auxiliary labels for all controlled substances. D is incorrect because auxiliary labels address drug-specific safety information, not patient allergy status.

Question 14

Under USP Chapter 795 and state laws, what beyond-use date (BUD) labeling is required for non-sterile compounded preparations?

  1. The BUD is optional for non-sterile preparations because they are not as sensitive as sterile preparations.
  2. The BUD must be identical to the expiration date of the longest-dated component used in the preparation.
  3. The BUD must be labeled based on USP 795 guidelines and stability data for non-sterile compounded preparations. (correct answer)
  4. The BUD must be set at exactly 14 days for all non-sterile compounded preparations regardless of stability data.
Explanation: Non-sterile compounded preparation labels must include a prominently displayed BUD determined per USP Chapter 795 guidelines and stability data. C correctly identifies this requirement. A is incorrect because BUD labeling is required, not optional. B is incorrect because the BUD is not simply the longest ingredient date; formulation-specific stability analysis governs. D is incorrect because a universal 14-day BUD is not the USP 795 standard; BUDs are determined based on formulation type and stability data.

Question 15

A compounding pharmacy prepares a patient-specific sterile preparation. Under USP Chapter 797 and applicable state law, what information must appear on the label of this compounded preparation?

  1. Patient name, drug name, strength, beyond-use date, and storage requirements. (correct answer)
  2. Only the drug name and beyond-use date.
  3. Only the patient name and preparation date.
  4. Only the pharmacy name and compounding pharmacist's initials.
Explanation: Compounded sterile preparation labels must be comprehensive: patient name, prescriber, active ingredients/strength, quantity/volume, pharmacy identity, directions, route, beyond-use date, storage requirements, preparation date, lot number, and compounder identity. A correctly identifies these comprehensive requirements. B is incorrect because drug name and beyond-use date alone are far below required compounded preparation labeling. C is incorrect because patient name and preparation date alone are insufficient. D is incorrect because pharmacy name and initials alone are far below required labeling.

Question 16

Under applicable state pharmacy law, which of the following most accurately describes the minimum label elements required on a prescription dispensing label for a retail pharmacy patient?

  1. Only the drug name and the prescriber's name.
  2. Only the patient's name and the directions for use.
  3. Only the pharmacy name and phone number.
  4. Pharmacy name, patient name, drug name, directions, and date dispensed. (correct answer)
Explanation: State pharmacy laws require comprehensive dispensing label elements: pharmacy name and address, patient name, prescriber name, dispense date, drug name and strength, quantity, directions for use, and pharmacist identification. Some states require additional elements such as refills remaining and auxiliary labels. D correctly identifies these core required components under applicable state law. A is incorrect because drug name and prescriber name alone are far below the required elements. B is incorrect because patient name and directions alone are insufficient. C is incorrect because pharmacy name and phone number alone are only two of many required label elements.

Question 17

Under most state pharmacy laws, if a drug product has a black box warning in its FDA-approved labeling, which of the following best describes the pharmacist's labeling and counseling obligation?

  1. No obligation exists beyond standard dispensing label requirements.
  2. The pharmacist must attach the full text of the black box warning to the dispensing label.
  3. The pharmacist need only provide the Medication Guide if one exists for the product.
  4. Apply required auxiliary labels and provide counseling on serious risks as per state law. (correct answer)
Explanation: A black box warning identifies serious, potentially life-threatening risks and informs the pharmacist's professional obligations, but the specific labeling and counseling duties derive from applicable Medication Guide requirements, REMS conditions, state pharmacy law, and professional standards -- not from the black box warning itself as an independent legal mandate. D correctly describes this framework. A is incorrect because the presence of a black box warning should heighten the pharmacist's attention to applicable labeling and counseling requirements, even if it does not create standalone duties beyond those defined in law and REMS. B is incorrect because attaching the full text of the black box warning to the dispensing label is not the standard obligation; applicable auxiliary labels and professional counseling addressing the serious risks are appropriate. C is incorrect because Medication Guide distribution is one element of compliance; other obligations including counseling consistent with state law and professional standards also apply.

Question 18

A pharmacist dispenses a 90-day supply of a statin for a mail-order patient. Under federal labeling requirements, which of the following must appear on the dispensing label?

  1. Pharmacy name and address, prescription number, patient name, prescriber name, date, and directions. (correct answer)
  2. Only the drug name and prescriber name because the patient already received counseling.
  3. Only the patient's insurance copay amount and refill date.
  4. Only the mail-order pharmacy's website address because patients can access label information electronically.
Explanation: Under 21 CFR 201.100, the federal dispensing label requirements for prescription drugs include the pharmacy name and address, prescription number, patient name and address, prescriber name, date dispensed, and directions for use. States commonly require additional elements such as drug name and strength, quantity, refills remaining, and pharmacist identification. A correctly identifies the federal baseline and notes that state law adds further elements. B is incorrect because prior counseling does not relieve the label of required elements. C is incorrect because insurance information is not a required label element. D is incorrect because a website address alone is not a substitute for required label information.

Question 19

Under state pharmacy law, what is generally required when a pharmacist dispenses a different manufacturer's generic drug than the one originally dispensed at the last refill?

  1. No action is required because generic substitution is automatic.
  2. The label must include the new manufacturer's name, and the patient must be informed of the change. (correct answer)
  3. The pharmacist must obtain prescriber authorization before dispensing a different generic manufacturer.
  4. The pharmacist must attach an explanatory note to the prescription bag but need not change the label.
Explanation: The label must reflect the actual product dispensed. When a different generic manufacturer is used, the patient should be counseled about appearance differences and confirmation of therapeutic equivalence. Some states require disclosure of generic manufacturer changes. B correctly identifies these obligations. A is incorrect because the label must be updated and patient counseling is warranted. C is incorrect because prescriber authorization is not required for generic manufacturer substitution among therapeutically equivalent products. D is incorrect because the label itself must reflect the actual dispensed product.

Question 20

A pharmacist receives a prescription for amoxicillin with directions that simply read 'take as directed.' Under labeling requirements, which of the following best applies?

  1. The pharmacist should print 'take as directed' on the label because that is what the prescriber ordered.
  2. The pharmacist must obtain specific dosing instructions from the prescriber before dispensing to ensure proper labeling. (correct answer)
  3. The pharmacist may dispense with 'take as directed' because the prescriber can provide verbal instructions to the patient.
  4. The pharmacist should add standard amoxicillin dosing directions from a reference and label accordingly without contacting the prescriber.
Explanation: Vague directions like 'take as directed' do not satisfy the labeling requirement for adequate directions for use. The pharmacist should contact the prescriber for specific dosing information. B correctly identifies this obligation. A is incorrect because inadequate prescriber directions do not excuse inadequate labeling. C is incorrect because the label itself must contain adequate directions regardless of verbal instructions at pick-up. D is incorrect because the pharmacist cannot unilaterally supply specific dosing without prescriber authorization.